{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T02:58:51Z","timestamp":1793588331720,"version":"4.5.0"},"reference-count":128,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jacc.2026.05.007","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T19:49:28Z","timestamp":1781034568000},"page":"589-612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0643-1859","authenticated-orcid":false,"given":"Sadiya S.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiadi E.","family":"Ndumele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Bhave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Coresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald M.","family":"Lloyd-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia C.","family":"Low Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela B.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurram","family":"Nasir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janani","family":"Rangaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence S.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2026.05.007_bib1","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib2","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"on behalf of the American Heart Association. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib3","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1001\/jama.2024.6892","article-title":"Prevalence of cardiovascular-kidney-metabolic syndrome stages in US adults, 2011-2020","volume":"331","author":"Aggarwal","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.007_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s44161-023-00391-y","article-title":"Cardiometabolic and renal phenotypes and transitions in the United States population","volume":"3","author":"Lhoste","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.jacc.2026.05.007_bib5","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.1161\/CIR.0000000000001307","article-title":"Risk-based primary prevention of heart failure: a scientific statement from the American Heart Association","volume":"151","author":"Khan","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib6","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJMe2503600","article-title":"Seeking multiorgan benefits with cardiovascular\u2013kidney\u2013metabolic drug therapy","volume":"392","author":"Zannad","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.007_bib7","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(25)01393-5","article-title":"Prioritising the primary prevention of heart failure","volume":"406","author":"Khan","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.007_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2026.03.056","article-title":"2026 AHA\/ACC\/ADA\/ASN guideline for the prevention, detection, evaluation and management of cardiovascular-kidney-metabolic syndrome: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","author":"Ndumele","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib10","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib11","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.jacc.2018.11.005","article-title":"Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology","volume":"73","author":"Lloyd-Jones","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib12","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jacc.2025.08.001","article-title":"Use of risk assessment to guide decision-making for blood pressure management in the primary prevention of cardiovascular disease: a scientific statement from the American Heart Association and American College of Cardiology","volume":"86","author":"Khan","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib13","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib14","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib15","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib16","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2024.02.013","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Gornik","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib18","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib19","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib20","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0000000000001078","article-title":"Life\u2019s Essential 8: updating and enhancing the American Heart Association\u2019s construct of cardiovascular health: a presidential advisory from the American Heart Association","volume":"146","author":"Lloyd-Jones","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib21","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1161\/CIR.0000000000001124","article-title":"Optimizing prepregnancy cardiovascular health to improve outcomes in pregnant and postpartum individuals and offspring: a scientific statement from the American Heart Association","volume":"147","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib22","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1161\/CIR.0000000000001212","volume":"149","author":"Lewey","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib23","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1161\/CIR.0000000000000912","article-title":"Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association","volume":"142","author":"El Khoudary","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib24","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes: 2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.05.007_bib25","first-page":"s114","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2026.05.007_bib26","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","article-title":"Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease","volume":"79","author":"Kanwal","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2026.05.007_bib27","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2026.05.007_bib28","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000988","article-title":"Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association","volume":"144","author":"Yeghiazarians","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib29","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2026.05.007_bib30","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJMra2403308","article-title":"Noninvasive assessment of liver fibrosis","volume":"393","author":"Castera","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.007_bib31","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2023.2854","article-title":"Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial","volume":"329","author":"Pagidipati","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.007_bib32","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib33","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"for the Chronic Kidney Disease Prognosis Consortium and the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group. Development and validation of the American Heart Association's PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib34","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1001\/jama.2025.2868","article-title":"Discordance of 10- and 30-year predicted risk for cardiovascular disease in US adults","volume":"333","author":"Krishnan","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.007_bib35","first-page":"e953","volume":"153","author":"Khan","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib36","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jacc.2015.07.066","article-title":"Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology\/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"66","author":"Nasir","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib37","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib38","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jcmg.2020.12.012","article-title":"Incorporating coronary calcium scoring into risk assessment for primary prevention","volume":"14","author":"Lloyd-Jones","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2026.05.007_bib39","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib40","first-page":"451","article-title":"Allocation of semaglutide according to coronary artery calcium and BMI: applying the SELECT trial to MESA","volume":"18","author":"Razavi","year":"2025","journal-title":"Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2026.05.007_bib41","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.038991","article-title":"Real-world evidence linking the Predicting Risk of Cardiovascular Disease Events Risk Score and coronary artery calcium","volume":"14","author":"Rhee","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.05.007_bib42","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.jacc.2025.09.1509","article-title":"Age and sex-specific percentiles of 30-year cardiovascular disease risk based on the PREVENT equations","volume":"86","author":"Krishnan","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib43","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1161\/CIRCULATIONAHA.120.045851","article-title":"The expected 30-year benefits of early versus delayed primary prevention of cardiovascular disease by lipid lowering","volume":"142","author":"Pencina","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib44","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ahj.2017.12.005","article-title":"Improving patient risk communication: translating cardiovascular risk into standardized risk percentiles","volume":"198","author":"Navar","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2026.05.007_bib45","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0140-6736(25)00055-8","article-title":"The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma","volume":"405","author":"Zaman","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.007_bib46","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1093\/eurheartj\/ehy217","article-title":"Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"39","author":"Budoff","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.05.007_bib47","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2010.461","article-title":"Coronary artery calcium score and risk classification for coronary heart disease prediction","volume":"303","author":"Polonsky","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.007_bib48","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa072100","article-title":"Coronary calcium as a predictor of coronary events in four racial or ethnic groups","volume":"358","author":"Detrano","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.007_bib49","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jcmg.2020.12.024","article-title":"Coronary artery calcium for the allocation of GLP-1RA for primary prevention of atherosclerotic cardiovascular disease","volume":"14","author":"Cainzos-Achirica","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2026.05.007_bib50","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jcmg.2021.10.017","article-title":"CAC for risk stratification among individuals with hypertriglyceridemia free of clinical atherosclerotic cardiovascular disease","volume":"15","author":"Cainzos-Achirica","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2026.05.007_bib51","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1161\/CIRCULATIONAHA.116.025471","article-title":"Coronary artery calcium to guide a personalized risk-based approach to initiation and intensification of antihypertensive therapy","volume":"135","author":"McEvoy","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib52","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1016\/j.jacc.2018.09.051","article-title":"Impact of statins on cardiovascular outcomes following coronary artery calcium scoring","volume":"72","author":"Mitchell","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib53","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.jcmg.2022.03.031","article-title":"The prognostic value of CAC zero among individuals presenting with chest pain: a meta-analysis","volume":"15","author":"Agha","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2026.05.007_bib54","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1161\/CIRCULATIONAHA.121.056705","article-title":"Determinants of incident atherosclerotic cardiovascular disease events among those with absent coronary artery calcium: Multi-Ethnic Study of Atherosclerosis","volume":"145","author":"Al Rifai","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib55","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jacr.2018.04.029","article-title":"Managing incidental findings on thoracic CT: mediastinal and cardiovascular findings: a white paper of the ACR Incidental Findings Committee","volume":"15","author":"Munden","year":"2018","journal-title":"J Am Coll Radiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib56","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jacc.2023.06.040","article-title":"Association of coronary artery calcium detected by routine ungated CT imaging with cardiovascular outcomes","volume":"82","author":"Peng","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib57","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jcct.2018.03.008","article-title":"CAC-DRS: coronary artery calcium data and reporting system: an expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT)","volume":"12","author":"Hecht","year":"2018","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.jacc.2026.05.007_bib58","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcct.2017.02.010","article-title":"Clinical indications for coronary artery calcium scoring in asymptomatic patients: expert consensus statement from the Society of Cardiovascular Computed Tomography","volume":"11","author":"Hecht","year":"2017","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.jacc.2026.05.007_bib59","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1161\/CIR.0000000000001382","volume":"152","author":"Foraker","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib60","doi-asserted-by":"crossref","DOI":"10.1148\/ryct.240548","article-title":"Coronary artery calcium scoring on dedicated cardiac CT and noncardiac CT scans","volume":"7","author":"Dzaye","year":"2025","journal-title":"Radiol Cardiothorac Imaging"},{"key":"10.1016\/j.jacc.2026.05.007_bib61","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jcct.2023.10.001","article-title":"Accuracy of incidental visual coronary artery calcium assessment compared with dedicated coronary artery calcium scoring","volume":"17","author":"Raygor","year":"2023","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.jacc.2026.05.007_bib62","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/jama.2025.21077","article-title":"Coronary computed tomography angiography in prediction of first coronary events","volume":"335","author":"Bergstr\u00f6m","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.007_bib63","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.125.018443","article-title":"Machine learning model for atherosclerosis evaluation and cardiovascular risk prediction based on coronary CT angiography: analysis from the CREATION registry","volume":"18","author":"Song","year":"2025","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2026.05.007_bib64","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejvs.2004.11.013","article-title":"Prevalence and prognostic significance of asymptomatic peripheral arterial disease in 68-year-old men with diabetes: results from the population study \u2018Men born in 1914\u2019 from Malm\u00f6, Sweden","volume":"29","author":"Ogren","year":"2005","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jacc.2026.05.007_bib65","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.jacc.2009.11.075","article-title":"Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) Study","volume":"55","author":"Nambi","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib66","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1001\/jama.2014.14681","article-title":"Nonobstructive coronary artery disease and risk of myocardial infarction","volume":"312","author":"Maddox","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.007_bib67","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.jacc.2024.06.045","article-title":"Influence of subclinical atherosclerosis burden and progression on mortality","volume":"84","author":"Fuster","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib68","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","volume":"27","author":"Bozkurt","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2026.05.007_bib69","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.125.013112","article-title":"Natriuretic peptide cut points for heart failure classification in individuals with and without obesity","volume":"18","author":"Chitsazan","year":"2025","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2026.05.007_bib70","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMoa031994","article-title":"Plasma natriuretic peptide levels and the risk of cardiovascular events and death","volume":"350","author":"Wang","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.007_bib71","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/CIRCHEARTFAILURE.111.964841","article-title":"Prediction of incident heart failure in general practice: the Atherosclerosis Risk In Communities (ARIC) Study","volume":"5","author":"Agarwal","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2026.05.007_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102659","article-title":"Predicted risk, preclinical heart failure measures, and incident heart failure: the ARIC Study","volume":"13","author":"Grant","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.05.007_bib73","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S2213-8587(16)30196-6","article-title":"Natriuretic Peptides Studies Collaboration. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis","volume":"4","author":"Willeit","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.05.007_bib74","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1161\/CIRCULATIONAHA.110.005264","article-title":"Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk In Communities Study","volume":"123","author":"Saunders","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib75","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1001\/jama.2010.1708","article-title":"Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults","volume":"304","author":"deFilippi","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.007_bib76","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jchf.2019.12.008","article-title":"High-sensitivity cardiac troponin I levels and prediction of heart failure: results from the BiomarCaRE Consortium","volume":"8","author":"Yan","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.05.007_bib77","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1001\/jamacardio.2021.3187","article-title":"Associations of high-sensitivity troponin and natriuretic peptide levels with outcomes after intensive blood pressure lowering: findings from the SPRINT randomized clinical trial","volume":"6","author":"Berry","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib78","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","article-title":"PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial","volume":"62","author":"Huelsmann","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib79","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.007_bib80","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1161\/CIRCULATIONAHA.118.038772","article-title":"High-sensitivity troponin I and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC Study","volume":"139","author":"Jia","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib81","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ejhf.286","article-title":"Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent's Screening to Prevent Heart Failure) study","volume":"17","author":"Ledwidge","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.05.007_bib82","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1681\/ASN.2014010108","article-title":"High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study","volume":"26","author":"Bansal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2026.05.007_bib83","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.041683","article-title":"CKD Prognosis Consortium. Predictive value of serum N-terminal pro-B-type natriuretic peptide and troponin T for incident heart failure: a meta-analysis of 9 international cohorts","volume":"14","author":"Bansal","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.05.007_bib84","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1161\/CIRCHEARTFAILURE.112.968701","article-title":"N-terminal pro-B-type natriuretic peptide, left ventricular mass, and incident heart failure: Multi-Ethnic Study of Atherosclerosis","volume":"5","author":"Choi","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2026.05.007_bib85","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1001\/jama.2010.1768","article-title":"Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population","volume":"304","author":"de Lemos","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.007_bib86","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41591-018-0240-2","article-title":"Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram","volume":"25","author":"Attia","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2026.05.007_bib87","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41586-020-2145-8","article-title":"Video-based AI for beat-to-beat assessment of cardiac function","volume":"580","author":"Ouyang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2026.05.007_bib88","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib89","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib90","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.05.007_bib91","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.007_bib92","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1186\/s12872-025-05278-3","article-title":"Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"Sadraei","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacc.2026.05.007_bib93","article-title":"Semaglutide for adults living with obesity","author":"Bracchiglione","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2026.05.007_bib94","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials","volume":"12","author":"Apperloo","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.05.007_bib95","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib96","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.007_bib97","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1161\/CIRCULATIONAHA.115.018383","article-title":"Individualized statin benefit for determining statin eligibility in the primary prevention of cardiovascular disease","volume":"133","author":"Thanassoulis","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100825","article-title":"The causal-benefit model to prevent cardiovascular events","volume":"3","author":"Kohli-Lynch","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacc.2026.05.007_bib99","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamacardio.2019.3665","article-title":"Statin use in primary prevention of atherosclerotic cardiovascular disease according to 5 major guidelines for sensitivity, specificity, and number needed to treat","volume":"4","author":"Mortensen","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib100","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/jamacardio.2024.3544","article-title":"Age-stratified risk categories for cardiovascular disease prevention therapies","volume":"9","author":"McCarthy","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib101","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.007_bib102","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2024.04.041","article-title":"Long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"222","author":"Moiz","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib103","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(21)01921-8","article-title":"Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis","volume":"398","author":"Rahimi","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.007_bib104","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.007_bib105","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.007_bib106","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.007_bib107","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.007_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002538","article-title":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: a meta-analysis of individual participant data","volume":"15","author":"Karmali","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacc.2026.05.007_bib109","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1161\/CIR.0000000000000920","volume":"142","author":"Rangaswami","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib110","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.007_bib110a","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-026-04437-z","article-title":"on behalf of the Chronic Kidney Disease Prognosis Consortium. Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals","author":"Neuen","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2026.05.007_bib111","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.125.074545","article-title":"Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial","volume":"151","author":"Marx","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib112","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.007_bib113","doi-asserted-by":"crossref","first-page":"e2326230","DOI":"10.1001\/jamanetworkopen.2023.26230","article-title":"Estimated prevalence and testing for albuminuria in US adults at risk for chronic kidney disease","volume":"6","author":"Chu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.05.007_bib114","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1001\/jama.2019.17379","article-title":"CKD Prognosis Consortium. Development of risk prediction equations for incident chronic kidney disease","volume":"322","author":"Nelson","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.007_bib115","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.2337\/dc22-0698","article-title":"CKD Prognosis Consortium. Development and validation of prediction models of adverse kidney outcomes in the population with and without diabetes","volume":"45","author":"Grams","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.05.007_bib116","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jacc.2025.05.009","article-title":"2025 AHA\/ACC statement on cost\/value methodology in clinical practice guidelines (update from 2014 statement): a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Kazi","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib117","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/jamacardio.2024.4657","article-title":"Semaglutide eligibility across all current indications for US adults","volume":"10","author":"Shi","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib118","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2337\/cd25-0018","article-title":"Triple agonist therapy: a new frontier in treating type 2 diabetes and obesity","volume":"43","author":"Whitley","year":"2025","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.jacc.2026.05.007_bib119","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1111\/dom.16618","article-title":"Novel oral agents in anti-obesity pharmacotherapy: a narrative review","volume":"27","author":"Buch","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2026.05.007_bib120","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMoa2504214","article-title":"Once-monthly maridebart cafraglutide for the treatment of obesity: a phase 2 trial","volume":"393","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.007_bib121","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1007\/s12325-020-01609-2","article-title":"Clinical outcomes and healthcare resource utilization in a real-world population reflecting the DAPA-CKD trial participants","volume":"38","author":"Olufade","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacc.2026.05.007_bib122","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/jamacardio.2025.1603","article-title":"AHA PREVENT equations and lipoprotein(a) for cardiovascular disease risk: insights from MESA and the UK Biobank","volume":"10","author":"Bhatia","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib123","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/jamacardio.2025.1865","article-title":"Performance of the American Heart Association's PREVENT equations among disaggregated racial and ethnic subgroups","volume":"10","author":"Yan","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib124","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/eurheartj\/ehae914","article-title":"Heart failure risk stratification using artificial intelligence applied to electrocardiogram images: a multinational study","volume":"46","author":"Dhingra","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.05.007_bib125","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jacc.2024.05.003","article-title":"Transforming cardiovascular care with artificial intelligence: from discovery to practice: JACC State-of-the-Art Review","volume":"84","author":"Khera","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib126","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jamacardio.2025.0492","article-title":"Artificial intelligence\u2013enabled prediction of heart failure risk from single-lead electrocardiograms","volume":"10","author":"Dhingra","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.05.007_bib127","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jamacardio.2025.2427","article-title":"PREVENT risk age equations and population distribution in US adults","volume":"10","author":"Krishnan","year":"2025","journal-title":"JAMA Cardiol"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726064934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726064934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:31:52Z","timestamp":1785853912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109726064934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":128,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0735109726064934"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.05.007","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}